Aramis Biosciences Receives FDA Clearance to Proceed with Phase 2 Trail of A197, a Novel Immunomodulatory Agent for the Treatment of Dry Eye Disease

Aramis Biosciences announced that the FDA has cleared the investigational new drug (IND) application for A197, enabling the company to proceed with a phase 2 proof of concept clinical trial.

“We are pleased that FDA has cleared A197 to move into phase 2 clinical trials in dry eye patients. We believe that A197, with its novel mechanism of action targeting the immunopathogenesis of the disease and clean tolerability profile, has the potential to significantly improve the standard of care in dry eye disease,” David S. Tierney, MD, Aramis Biosciences’ President and CEO, said in a company news release. “With less than 5 percent of dry eye patients satisfied with available treatments, we look forward to moving this promising investigational therapy into the clinic.”